Navigation Links
Teach Prescribers About Dangers of Long-Acting Pain Meds: FDA
Date:7/9/2012

By Steven Reinberg
HealthDay Reporter

MONDAY, July 9 (HealthDay News) -- As part of its efforts to curb the abuse of narcotic painkillers, the U.S. Food and Drug Administration is requiring drug makers to educate doctors about the risks of long-acting and extended-release forms of the drugs.

"Prescription-drug abuse is our nation's fastest-growing drug problem," FDA commissioner Dr. Margaret Hamburg said during a Monday afternoon press conference.

Commonly prescribed drugs that come in longer-acting forms include oxycodone, morphine and fentanyl.

The continuing-education programs will be based on FDA-created blueprints. The agency expects the more than 20 companies that make these drugs to provide grants to firms that specialize in medical continuing education. These firms will, in turn, develop and administer the programs under FDA supervision and provide them to doctors for free.

Although all opioid painkillers carry risk of abuse, overdose and death, the extended-release and time-release forms of the drugs are particularly risky. Because they act in the body over longer periods, they are more likely to cause problems, Hamburg said.

"The number of people harmed by these long-acting or extended-release opioids due to misprescribing, misuse and abuse ... continues to increase dramatically," Hamburg said.

In 2008, nearly 15,000 Americans died from overdoses of these drugs. In 2009, there were more than 15,500 deaths from opioid painkillers -- almost four times as many as in 1999, according to the U.S. Centers for Disease Control and Prevention.

In addition, more than 2 million emergency-room visits in 2010 involved abuse or misuse of prescription drugs -- almost half of all drug-related visits. Of these visits, more than 15 percent involved opioid medications, Hamburg said.

The drugs are widely prescribed. It is estimated that nearly 23 million prescriptions for extended-release and long-acting opioids were issued in 2011, Hamburg said. It is estimated that more than 320,000 prescribers listed with the U.S. Drug Enforcement Administration wrote at least one prescription for opioid painkillers in 2011, according to the FDA.

Despite these problems, Hamburg said, patients who need these drugs must have access to them.

"Educating health care professionals on how to safely prescribe extended-release and long-acting opioids is essential to address this critical public health issue," she said.

The FDA hopes that over the next three years, 60 percent of the 320,000 prescribing doctors will have been trained, Hamburg said.

Along with the programs for doctors, the FDA also is mandating that manufacturers provide FDA-approved patient-education materials on the safe use of these drugs. The material appears on a single page in consumer-friendly language, and will be given to patients every time they fill a prescription.

Both the drug companies and the FDA will review the progress and success of these programs. Based on the reviews, the agency may require the companies to provide additional elements to ensure success.

The first programs under the FDA's new requirement are expected to be launched by March 1. Although no doctor currently is required to take the two- to three-hour continuing-education program, the Obama administration is urging Congress to make such programs mandatory.

More information

For more about narcotic painkillers, visit the U.S. National Library of Medicine.

SOURCES: July 9, 2012, press conference with Margaret Hamburg, M.D., commissioner, U.S. Food and Drug Administration; FDA news release, July 9, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. To Improve School Nutrition, Involve Teachers and Parents
2. Funding for teacher classroom management study
3. Fathers Can Teach Their Children Persistence: Study
4. Teaching autistic teens to cope
5. Fewer prostate cancer surgery complications found in teaching hospitals with fellowship programs
6. What can Hollywood teach us about our planet?
7. University of Louisville study dispels concerns about drive-thru flu clinics
8. Study answers Medicare concerns about paying for CT colonography
9. PawnUp.com Online Pawn Shop Spreads Awareness About its Small Business Loans.
10. Suffering of Thousands Prompts FDA Hearing about Hip Implants
11. Study calls for drug trial patients to receive more information about effects of placebos
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Teach Prescribers About Dangers of Long-Acting Pain Meds: FDA
(Date:3/23/2017)... Kennett Square, PA (PRWEB) , ... March 23, 2017 , ... ... sunny days. That means many students are thinking about summer internships , which ... (or lack thereof). , The pros at Garden Media Group, a boutique public relations ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... products at competitive pricing. Verisys through its FACIS and other ... restrictions and Disciplinary actions. , “We are delighted to be able to offer ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... stands with all Americans facing life-altering and fatal diseases in opposition to the ... shortsighted decisions that would eviscerate care, services, and hope for the most vulnerable ...
(Date:3/23/2017)... ... March 23, 2017 , ... On ... Dagger Foundation the US Special Operations Command’s Patriot Award. The award was presented ... thanked Task Force Dagger Foundation for its significant and enduring support to the ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The Boulevard ... 10am - 2pm. All events will be located in the Main West Entrance ... a no-cost Child ID event. No appointment is necessary and each child with a ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Md. , March 23, 2017  The U.S. ... Bavencio (avelumab) for the treatment of adults and pediatric ... carcinoma (MCC), including those who have not received prior ... MCC, a rare, aggressive form of skin cancer. ... common cancers, patients with a rare form called Merkel ...
(Date:3/23/2017)... VANCOUVER, British Columbia , March 23, ... ) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical ... diseases, today announced that data from its successful Phase ... a focal treatment for localized prostate cancer, will be ... the 32 nd Annual European Association of Urology ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... their offering. ... The global oxygen therapy devices market to grow at a CAGR ... Global Oxygen Therapy Devices Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology: